With the rapid spread of viral hepatitis and other diseases in the world, the demand for therapeutic drug has increased sharply in recent years, which promotes the rapid development of vidarabine monophosphate market. The data statistics of Chinese Hospital Association shows that the drug cost of vidarabine monophosphate for injection has reached CNY 67.6 million in 690 large hospitals of China’s 84 cities. Plus a small number of other urban hospitals which are not counted, the sales amount of vidarabine monophosphate for injection reached about CNY75 million in China in 2011.
The overall production capacity of China’s vidarabine monophosphate was estimated to be about CNY 100 million in 2011. And about CNY 30 million was used in export which mainly faced for India, Germany and other countries.
Key highlights of the report:
? Market status of Vidarabine Monophosphate for Injection in Chinese Hospitals
? Production Capacity and Main Distribution Area
? Demand Characteristics and Main Distribution Area
? Development Trend of Product Technology
? Product Price Trend and Influence Factor
? Project Investment Suggestion and Risk Alarm
1. Product Overview of China’s Vidarabine Monophosphate Product
1.1 Definition, Property and Application Characteristics
1.2 Development History
2. Overseas Market of Vidarabine Monophosphate
3. Environment of Vidarabine Monophosphate in China
3.1 Analysis of China’s Economic Development Environment
3.1.1 Analysis of GDP
3.2.2 Analysis of Fixed Assets Investment
3.2.3 Income Analysis of Urban and Rural Residents
3.1.4 Forecast of Macro Economic Development in China
3.2 Relevant Industrial Policies, Standards and Laws and Regulations
4. Market Characteristics Analysis of Vidarabine Monophosphate
4.1 Analysis and Forecast of Market Concentration ?
4.2 Analysis and Forecast of SWOT
4.2.1 Strength
4.2.2 Weakness
4.2.3 Opportunity
4.2.4 Threat
4.3 Analysis and Forecast of Enter and Exit Status
5. Development of China’s Vidarabine Monophosphate
5.1 Current Situation and Forecast of Vidarabine Monophosphate in China
5.2 Analysis and Forecast of Output in China
5.2.1 Overall Production Scale of Vidarabine Monophosphate Industry
5.2.2 Production Area Distribution of Vidarabine Monophosphate
5.3 Analysis and Forecast of Market Demand of Vidarabine Monophosphate in China
5.3.1 Demand Characteristics
5.3.2 Main Region Distribution
5.4 Analysis of Price Trend of Vidarabine Monophosphate in China
5.4.1 Price Trend of Vidarabine Monophosphate in China from 2010 to 2011
5.4.2 Current Price of Vidarabine Monophosphate in China
5.4.3 Factors affecting Market Price
5.4.4 Forecast of Price Trend of Vidarabine Monophosphate in China from 2013 to 2015
6. Import and Export of Vidarabine Monophosphate in China
6.1 Analysis of Import Situation
6.2 Analysis of Export Situation
7. Analysis of Technical Development of China’s Vidarabine Monophosphate
7.1 Analysis of Current Technology Development Situation in China
7.2 Analysis of Technical Maturity
7.3 Analysis of Technical Gap between Home and Abroad and Influence Factors
7.4 Strategies of Technical Improvement in China
8. Major Manufacturers of Vidarabine Monophosphate in China
8.1 Hainan Chuntch Pharmaceutical Co., Ltd
8.2 Guangdong Xianqiang Pharmaceutical Co., Ltd
8.3 Henan Furen Huaiqingtang Pharmaceutical Co., Ltd
8.4 Hainan Hualon Pharmaceutical Co., Ltd
8.5 Nanjing Hicin Pharmaceutical Co., Ltd
9. Investment Suggestion of Vidarabine Monophosphate
9.1 Analysis of Investment Environment
9.2 Analysis of Investment Risk
9.3 Investment Suggestion
10. Future Development Forecast and Investment Prospect of Vidarabine Monophosphate in China
10.1 Forecast of Industrial Development Trend
10.1.1 Analysis of Industrial Development in the Future
10.1.2 Analysis of Technique Development in the Future
10.1.3 “Twelfth Five-year Plan” of the Whole Industry and Prospect
10.2 Forecast of Industrial Operation Situation from 2013 to 2017
11. Investment Advice from Industry Experts of Vidarabine Monophosphate in China
11.1 Investment Opportunity
11.2 Investment Risk
11.2.1 Risk of Horizontal Competition
11.2.2 Credit Risk
11.2.3 Influence of Policy Change
11.3 Industrial Coping Strategy
11.3.1 Implement of Competitive Strategic Alliance
11.3.2 Coping Strategy of the Enterprise
11.4 Implement of Key Account Strategy
11.4.1 Analysis of Necessity ?
11.4.2 Establish Key Account
11.4.3 Marketing Strategy to Key Account
11.4.4 Strengthen the Management to Key Account
11.4.5 Solve the Key Problems to Implement the Key Account Strategy
List of Figures
Figure 1. Proportion and Growth of Anti-herpes Drug in the Antiviral Drugs in Sample Hospitals of the Global Key Cities
Figure 2. Year-on-year Growth of GDP from 2010 to 2011
Figure 3. Year-on-year Growth of Domestic Fixed-asset Investments in 2011
Figure 4. Actual Growth of Disposable Income of Urban Residents in 2011
Figure 5. Actual Growth of Per Capita Income of Rural Residents in 2011
Figure 6. Sales Amount Statistical of Vidarabine Monophosphate for Injection in Hospitals of China’s Key City in 2011
Figure 7. Average Price Chart of 100 MG Vidarabine Monophosphate for Injection from the First Quarter of 2010 to the Fourth Quarter of 2011
Figure 8. Imported Quantity and Amount Increase Chart of Vidarabine Monophosphate from 2009 to 2011
Figure 9. Top 20 Countries and Regions of Import Volume from 2011 to 2012
Figure 10. Exported Quantity and Amount Increase Chart of Vidarabine Monophosphate from 2009 to 2011
Figure 11. Top 20 Countries and Regions of Export Volume in 2011
Figure 12. Main Financial Index of Hainan Chuntch Pharmaceutical Co., Ltd
Figure 13. Main Financial Index of Guangdong Xianqiang Pharmaceutical Co., Ltd
Figure 14. Main Financial Index of Henan Furen Huaiqingtang Pharmaceutical Co., Ltd
Figure 15. Main Financial Index of Hainan Hualon Pharmaceutical Co., Ltd
Figure 16. Main Financial Index of Nanjing Hicin Pharmaceutical Co., Ltd
